

Gisle Langslet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9112667/publications.pdf>

Version: 2024-02-01

49
papers

4,896
citations

236612

25
h-index

214527

47
g-index

50
all docs

50
docs citations

50
times ranked

5015
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment goals in familial hypercholesterolaemia—time to consider low-density lipoprotein-cholesterol burden. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2278-2280.	0.8	5
2	Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. <i>Journal of Clinical Lipidology</i> , 2021, 15, 134-141.	0.6	6
3	Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia. <i>Atherosclerosis</i> , 2021, 316, 48-52.	0.4	5
4	Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. <i>Journal of Clinical Lipidology</i> , 2021, 15, 375-378.	0.6	2
5	Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100180.	1.3	16
6	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097525.	0.9	9
7	Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 515-523.	1.3	2
8	Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 560958.	1.6	2
9	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2132-2146.	1.2	101
10	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5253-5262.	1.8	4
11	Familial hypercholesterolemia and young patients' thoughts on own condition and treatment. <i>Patient Education and Counseling</i> , 2019, 102, 1005-1012.	1.0	3
12	LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2019, 13, 279-286.	0.6	39
13	Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. <i>Journal of Clinical Lipidology</i> , 2019, 13, 138-147.	0.6	14
14	The heart failure burden of type 2 diabetes—a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018, 23, 303-323.	1.7	41
15	Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH. <i>Journal of Clinical Lipidology</i> , 2018, 12, 748-755.e2.	0.6	19
16	Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". <i>Circulation</i> , 2018, 137, 641-642.	1.6	1
17	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq1 1 0.784314 rgBT19 Overlook	1.3	14
18	Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. <i>Journal of Clinical Lipidology</i> , 2018, 12, 375-382.	0.6	29

#	ARTICLE	IF	CITATIONS
19	Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 390-396.e8.	0.6	51
20	Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1463-1470.	0.6	2
21	Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. <i>Atherosclerosis</i> , 2018, 278, 307-314.	0.4	45
22	Author's response to: letter to the editor. <i>Heart Failure Reviews</i> , 2018, 23, 819-819.	1.7	0
23	Some children with a familial hypercholesterolemia mutation may exhibit persistent low LDL levels. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1327-1328.	0.6	3
24	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1199-1207.	0.6	24
25	Response to the editor. <i>Heart Failure Reviews</i> , 2018, 23, 819.	1.7	0
26	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 195-203.e4.	0.6	56
27	Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 359-366.	1.6	84
28	Long-term Low-Density Lipoprotein Cholesterol Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. <i>JAMA Cardiology</i> , 2017, 2, 598.	3.0	137
29	Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1338-1346.e7.	0.6	38
30	Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolemia is not a good idea. <i>European Heart Journal</i> , 2016, 37, 1357-1359.	1.0	8
31	A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1153-1162.e3.	0.6	30
32	A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. <i>Atherosclerosis</i> , 2016, 254, 254-262.	0.4	91
33	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. <i>Diabetes Therapy</i> , 2016, 7, 269-278.	1.2	14
34	Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. <i>Journal of Clinical Lipidology</i> , 2015, 9, 778-785.	0.6	19
35	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1489-1499.	13.9	1,838
36	Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. <i>Journal of Clinical Lipidology</i> , 2015, 9, 741-750.	0.6	42

#	ARTICLE	IF	CITATIONS
37	Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2015, 13, 477-488.	0.6	50
38	Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet, The, 2015, 385, 2153-2161.	6.3	92
39	Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. Journal of Pediatrics, 2015, 167, 338-343.e5.	0.9	40
40	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370.	1.0	395
41	Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care, 2015, 38, 355-364.	4.3	197
42	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387.	1.4	15
43	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340.	6.3	615
44	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	1.2	316
45	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. Cardiovascular Drugs and Therapy, 2014, 28, 281-289.	1.3	86
46	Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis, 2014, 233, 561-567.	0.4	48
47	Eprotrirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes and Endocrinology, the, 2014, 2, 455-463.	5.5	84
48	Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2013, 11, 1061-1066.	0.6	23
49	Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2010, 55, 1121-1126.	1.2	136